Syngene International Limited has informed the Exchange about Investor Presentation
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Syngene International submitted its investor presentation for Q4 and FY26 ended March 31, 2026, to be used for analyst and institutional investor meetings. Full-year FY26 revenue rose a modest 3% YoY to Rs 3,739 Cr (~USD 419 Mn), while operating EBITDA margin contracted sharply to 26% from 30% in FY25, driving a 20% YoY drop in profit before exceptional items to Rs 380 Cr. Q4 FY26 was particularly weak, with EBITDA margin at 30.8% (vs 35% a year ago) and PAT before exceptional items falling 16% to Rs 153 Cr despite 2% revenue growth, hit by higher staff costs (up 14% for the year) and a large foreign exchange loss of Rs 61 Cr. Operationally, the company commenced operations at its new ADC discovery lab, completed 85 audits in FY26, and was included in the S&P Global Sustainability Yearbook 2026. Key leadership changes were announced: Kiran Mazumdar-Shaw moved to Executive Chairperson, Siddharth Mittal (from Biocon) takes over as MD & CEO from July 2026, replacing Peter Bains, and two other senior leaders from Biocon were appointed.
Shareholders should brace for continued near-term margin pressure, as profitability has clearly deteriorated despite steady revenue growth, and a major leadership transition at the CEO level could add short-term execution risk. However, the new investments in ADC capabilities, strong client base (16 of top 20 pharma), and net cash position of Rs 1,800 Cr provide a cushion for long-term growth.